2024-03-27 19:50:00 ET
Summary
- Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation.
- It is said that the GLP-1 market could exceed $100 billion by 2030.
- Results from the phase 2b IMPACT study, using pemvidutide for the treatment of patients with MASH, expected to be released Q1 of 2025.
- Altimmune had $198 million in cash as of December 31st of 2023; It will likely have to continue to tap into the ATM agreement or find another way to raise cash to fund its pipeline.
Altimmune ( ALT ) had just reported an update form its phase 2 MOMENTUM trial, which used its drug pemvidutide for the treatment of patients with obesity. In the latest data update for it, it noted that the weight loss patients experienced was comparable to that of typical diet and exercise. Investors should not only care about this because of the possible way that the company could differentiate pemvidutide compared to that of competing drugs, but also because this creates another catalyst opportunity with respect to this program. That is, it is expected that the full data set from this phase 2 MOMENTUM 48-week study is going to be presented at an upcoming medical conference. Besides this program, I believe that further value can be unlocked here. How so? Well, that's because pemvidutide may end up being a versatile type of drug, in that it could possibly also be used to treat patients with metabolic dysfunction-associated steatohepatitis [MASH]....
Read the full article on Seeking Alpha
For further details see:
Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place